MACHINE PREP: Dr. Ling Zhang, left, and Dr. Gregory D. Jay, owner of Lubris LLC, prepare the AKTA machine to purify antibodies at the Lubris lab. Lubris has licensed the glycoprotein lubricin to Novartis to use as a dry-eye treatment. / PBN PHOTO/ RUPERT WHITELEY
Dr. Gregory D. Jay, owner of Lubris LLC, is celebrating his company’s licensing of lubricin as a clinically superior dry-eye treatment to Novartis, which will fund its development as an equally promising treatment for damaged joints and abdominal scarring prevention. Lubricin, Jay explained, is a mucin – a glycoprotein found in the secretions of mucous…
You must be a paid subscriber to read this content.
To keep reading and receive unlimited access subscribe today for only $1.
Subscribe NowAlready a Subscriber?
Login now
Want to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.
Want to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.
